EMFRET R300 产品说明书
世界*实验材料供应商 emfret 上海金畔生物为其中国代理, emfret 在一直是行业的*,一直为广大科研客户提供zui为的产品和服务,上海金畔生物一直秉承为中国科研客户带来的产品,的服务, emfret 就是为了给广大科研客户带来更加完善的产品和服务,您的满意将是我们zui大的收获
emfret 中国代理, emfret 上海代理, emfret 北京代理,emfret 广东代理, emfret 江苏代理emfret 湖北代理,emfret 天津,emfret 黑龙江代理,emfret 内蒙古代理,emfret 吉林代理,emfret 福建代理,emfret 江苏代理, emfret 浙江代理, emfret 四川代理,
德国EMFRET公司专注心血管和血液系统研究用抗体研发和生产,供应的抗体包括清除血液中血小板、流式细胞术鉴定分析小鼠血小板表面糖蛋白,EMFRET公司的抗体不仅适用于流失分析、WB检测,还可用于免疫组化/免疫荧光及免疫共沉淀检测。
|
Antibodies for Plaet Depletion in Mice |
# R300 |
|
Product Information |
|
Catalog Number: |
R300 (lot # M) |
Isotype: |
Rat IgG (Wistar) |
Contents: |
0.5 mg purified immunoglobulins in PBS, sterile filtered |
Concentration: |
0.5 mg/ml |
For research use only, not for diagnostic or therapeutic use. This product is no medical device.
Specificity: This antibody preparation contains a mixture of purified rat monoclonal antibodies
directed against mouse GPIba (CD42b). Targeting of this receptor with divalent IgGs results in profound and irreversible Fc-independent plaet depletion in mice1,2. Plaet depletion is frequently used to study the general role of plaets in (patho-) physiology3.
Preparation and Storage: The antibodies were purified from hybridoma cell culture supernatant by Protein G-Sepharose chromatography and contain < 0.00025 ng/µg (< 0.0025 EU/µg) protein endotoxin. Stable for six months from date of shipment when stored at 4°C. KEEP STERILE, the preparation contains no preservative. Aliquots can be stored at -20°C for at least one year. Avoid repeated freezing and thawing.
Usage: This preparation is optimized to reduce the plaet count by >95% within 60 minutes after intravenous injection of 2 µg/g bodyweight. It is recommended to inject the antibodies in a volume of 100-200 µl (diluted with sterile PBS).
Depletion of mouse plaets by anti-GPIba treatment
Wild type mice received 2 or 4 µg/g plaet depletion antibodies in 200 µl sterile PBS intravenously and plaet counts were determined at the indicated time points. Results are mean ± s.d. of 6 mice per group.
- Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, and Zirngibl H. (2000) Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 96:2520-27.
- Elzey BD, Tian J, Jensen RJ et al. (2003) Plaet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity.19:9-19.
R300 | Antibodies for Mouse Plaet Depletion | polyclonal anti-GPIb alpha | Rat IgG | purif. | plaet depletion | 0.5 mg |
其它产品信息如下:
货号 |
抗原类型 |
克隆方式 |
表型 |
产品形式 |
应用 |
规格 |
C301 |
清除小鼠血小板 |
polyclonal non-immune rat immunoglobulins |
Rat IgG |
纯化 |
清除小鼠血小板 |
0.5 mg |
D200 |
双色分析血小板活性 |
Wug.E9 JON/A |
Rat IgG2b/IgG1 |
FITC、PE |
流式细胞术 |
2 x 1.0 ml; 200 tests |
M011-0 |
GPVI |
JAQ1 |
Rat IgG2a |
纯化 |
IP, IHC, WB |
0.1 mg |
M011-1 |
GPVI |
JAQ1 |
Rat IgG2a |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M021-0 |
Integrin alphaIIbbeta3 (GPIIb/IIIa, CD41/CD61) |
Leo.H4 |
Rat IgG2b |
purif. |
IP, IHC, block |
0.5 mg |
M021-1 |
Integrin alphaIIbbeta3 (GPIIb/IIIa, CD41/CD61) |
Leo.H4 |
Rat IgG2b |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M022-0 |
Integrin alphaIIbbeta3 (GPIIb/IIIa, CD41/CD61) |
Leo.A1 |
Rat IgG1 |
purif. |
IP, IHC |
0.5 mg |
M023-2 |
Integrin alphaIIbbeta3 (GPIIb/IIIa, CD41/CD61) |
JON/A |
Rat IgG2b |
PE |
FC (activ. form) |
1.5 ml; 300 tests |
M024-0 |
Integrin alphaIIb (GPIIb, CD41) |
MwReg30 |
Rat IgG1 |
purif. |
IP, IHC, generation of Fab fragments |
6 mg |
M025-0 |
Integrin alphaIIbbeta3 (GPIIb/IIIa, CD41/CD61) |
Leo.F2 |
Rat IgG2a |
purif. |
IP, IHC |
0.5 mg |
M025-1 |
Integrin alphaIIbbeta3 (GPIIb/IIIa, CD41/CD61) |
Leo.F2 |
Rat IgG2a |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M025-2 |
Integrin alphaIIbbeta3 (GPIIb/IIIa, CD41/CD61) |
Leo.F2 |
Rat IgG2a |
PE |
FC, IHC |
1.5 ml; 300 tests |
M025-3 |
Integrin alphaIIbbeta3 (GPIIb/IIIa, CD41/CD61) |
Leo.F2 |
Rat IgG2a |
DyLight 649 |
FC, IHC |
1.5 ml; 300 tests |
M030-0 |
Integrin beta3 chain (GPIIIa, CD61) |
Luc.A5 |
Rat IgG2a |
purif. |
IP, IHC, WB |
0.5 mg |
M031-0 |
Integrin beta3 chain (GPIIIa, CD61) |
Luc.H11 |
Rat IgG2b |
purif. |
IP, IHC, WB |
0.5 mg |
M031-1 |
Integrin beta3 chain (GPIIIa, CD61) |
Luc.H11 |
Rat IgG2b |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M040-0 |
GPIbalpha (CD42b) |
Xia.G5 |
Rat IgG2b |
purif. |
IP, IHC |
0.5 mg |
M040-1 |
GPIbalpha (CD42b) |
Xia.G5 |
Rat IgG2b |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M040-2 |
GPIbalpha (CD42b) |
Xia.G5 |
Rat IgG2b |
PE |
FC, IHC |
1.5 ml; 300 tests |
M040-3 |
GPIbalpha (CD42b) |
Xia.G5 |
Rat IgG2b |
DyLight 649 |
FC, IHC |
1.5 ml; 300 tests |
M041-0 |
GPIbalpha (CD42b) |
Xia.H10 |
Rat IgG2a |
purif. |
FC, IHC |
0.5 mg |
M041-1 |
GPIbalpha (CD42b) |
Xia.H10 |
Rat IgG2a |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M042-0 |
GPIbalpha (CD42b) |
Xia.G7 |
Rat IgG1 |
purif. |
IP, IHC, WB |
0.5 mg |
M042-1 |
GPIbalpha (CD42b) |
Xia.G7 |
Rat IgG1 |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M043-0 |
GPIbalpha (CD42b) |
Xia.B2 |
Rat IgG2a |
purif. |
IP, IHC, block |
0.5 mg |
M043-1 |
GPIbalpha (CD42b) |
Xia.B2 |
Rat IgG2a |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M050-0 |
GPIbbeta (CD42c) |
Xia.C3 |
Rat IgG2a |
purif. |
IP, IHC, WB |
0.5 mg |
M050-1 |
GPIbbeta (CD42c) |
Xia.C3 |
Rat IgG2a |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M051-0 |
GPIX (CD42a) |
Xia.B4 |
Rat IgG1 |
purif. |
IP, IHC |
0.5 mg |
M051-1 |
GPIX (CD42a) |
Xia.B4 |
Rat IgG1 |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M060-1 |
GPV (CD42d) |
Gon.C2 |
Rat IgG1 |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M061-1 |
GPV (CD42d) |
Gon.G6 |
Rat IgG2a |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M070-0 |
Integrin alpha2 chain (CD49b, GPIa) |
Sam.G4 |
Rat IgG2b |
purif. |
IP, IHC, block |
0.5 mg |
M070-1 |
Integrin alpha2 chain (CD49b, GPIa) |
Sam.G4 |
Rat IgG2b |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M071-0 |
Integrin alpha2 chain (CD49b, GPIa) |
Sam.C1 |
Rat IgG2b |
purif. |
IP, IHC |
0.5 mg |
M071-1 |
Integrin alpha2 chain (CD49b, GPIa) |
Sam.C1 |
Rat IgG2b |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M075-0 |
Integrin alpha2 chain (CD49b, GPIa) |
Sam.C1, Sam.G4, Sam.H9 |
Rat IgG2b/IgG1 |
purif. |
IP, IHC |
0.5 mg |
M080-0 |
Integrin alpha5 chain (CD49e) |
Tap.A12 |
Rat IgG1 |
purif. |
IP, IHC |
0.5 mg |
M080-1 |
Integrin alpha5 chain (CD49e) |
Tap.A12 |
Rat IgG1 |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M110-0 |
CD9 |
Nyn.H3 |
Rat IgG2a |
purif. |
IP, IHC, WB |
0.5 mg |
M110-1 |
CD9 |
Nyn.H3 |
Rat IgG2a |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M120-0 |
CD31 (PECAM-1) |
Pec.H3 |
Rat IgG1 |
purif. |
IP, IHC, WB |
0.5 mg |
M130-0 |
CD62P (P-selectin) |
Wug.E9 |
Rat IgG1 |
purif. |
IP, IHC |
0.5 mg |
M130-1 |
CD62P (P-selectin) |
Wug.E9 |
Rat IgG1 |
FITC |
FC, IHC |
1.5 ml; 300 tests |
M130-2 |
CD62P (P-selectin) |
Wug.E9 |
Rat IgG1 |
PE |
FC, IHC |
1.5 ml; 300 tests |
P140-1 |
fibrinogen |
polyclonal |
Rabbit IgG |
FITC |
FC, IHC |
1.5 ml; 300 tests |
P150-1 |
von Willebrand Factor (vWF) |
polyclonal |
Rabbit IgG |
FITC |
FC, IHC |
1.5 ml; 300 tests |
P180-1 |
negative control |
polyclonal |
Rabbit IgG |
FITC |
FC, IHC |
1.0 ml; 200 tests |
P190-1 |
negative control |
polyclonal |
Rat IgG |
FITC |
FC, IHC |
1.0 ml; 200 tests |
P190-2 |
negative control |
polyclonal |
Rat IgG |
PE |
FC, IHC |
1.0 ml; 200 tests |
|
||||||
P190-3 |
negative control |
polyclonal |
Rat IgG |
DyLight 649 |
FC, IHC |
1.0 ml; 200 tests |
R300 |
Antibodies for Mouse Plaet Depletion |
polyclonal anti-GPIb alpha |
Rat IgG |
purif. |
plaet depletion |
0.5 mg |
X488 |
Antibodies for In Vivo Mouse Plaet Labeling |
anti – GPIbbeta derivative |
Rat IgG |
DyLight 488 |
in vivo |
100 µg |
X649 |
Antibodies for In Vivo Mouse Plaet Labeling |
anti – GPIbbeta derivative |
Rat IgG |
DyLight 649 |
in vivo |
100 µg |